Drug intelligence / Profile preview

kangdaprevir

Development stage: Phase 1
Lead developer: Dongguan Dongyangguang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Kangdaprevir is a direct-acting antiviral drug developed in China, primarily as an inhibitor of the hepatitis C virus (HCV) NS3/NS4A protease. This enzyme is essential for viral replication, and its inhibition disrupts the life cycle of HCV. Kangdaprevir was initially developed by Dongguan Dongyangguang Pharmaceutical R&D Co. Ltd., and it has been investigated for use in treating chronic hepatitis C infection[1][2]. The drug belongs to the class of NS3/NS4A inhibitors, which are commonly used as part of combination therapies for HCV.

Other names: kangdaprevir sodium

Targets

NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)

Beyond the preview

Go deeper on kangdaprevir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kangdaprevir.

Explore the full profile